Kezar Life Sciences Inc.
KZR
NGS
Sector: Healthcare
Industry: Biotechnology
8.72
USD
0.31
(3.69%)
Optionable: Yes Market Cap: 575 M 90-day average vol: 1,029,962
Previous close: 8.41 Open: 8.56 Bid: 8.81 Ask: 8.81
52 week range
4.31 18.55
Last updated: Thursday 29th September 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 1.84 |
PE Ratio (TTM) | -7.60 |
Book Value per Share ($) | 4.35 |
5 Year PE Range-15.7 |
Returns
7 Day Return | 8.32% | |
1 Month Return | -11.74% | |
3 Month Return | 5.44% | |
1 Year Return | -1.69% | |
3 Year Return | 165.85% | |
5 Year Return | -50.87% | |
YTD Return | -47.85% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 44.81 |
14 Day SMA ($) | 8.91 |
14 Day EMA ($) | 8.77 |
Money Flow Index | 50.55 |
Average True Range | 0.54 |
50 Day SMA ($) | 9.69 |
200 Day SMA ($) | 11.25 |
ADX | 21.93 |
MACD | -0.42 |
Growth
Free Cash Flow QoQ Growth | -2.13% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -3.85% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
News
Financials
KZR Income Statement
Annual
| Invalid date | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of sales | -154000 | -175000 | -214000 | -322000 | -2 M | -3 M | |
| Gross operating profit | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling Gen & administrative expense | 2 M | 2 M | 7 M | 10 M | 12 M | 16 M | |
| Research & development expense | 7 M | 6 M | 18 M | 27 M | 31 M | 39 M | |
| Operating income | -9 M | -9 M | -25 M | -37 M | -43 M | -55 M | |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other income net | 0 | 0 | 0 | 0 | 0 | 0 | |
| Pre-tax Income (EBT) | -9 M | -9 M | -23 M | -35 M | -42 M | -55 M | |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income from total operations | -9 M | -9 M | -23 M | -35 M | -42 M | -55 M | |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total net income | -9 M | -9 M | -23 M | -35 M | -42 M | -55 M | |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | |
| Net income available for common | -9 M | -9 M | -23 M | -35 M | -42 M | -55 M | |
| Depreciation | 154000 | 175000 | 214000 | 322000 | 2 M | 3 M | |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating income before depreciation (EBITDA) | -9 M | -9 M | -24 M | -36 M | -40 M | -53 M | |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | |
| Basic EPS total | -0.69 | -0.65 | -2.26 | -1.84 | -0.95 | -1.04 | |
| Diluted EPS total | -0.69 | -0.65 | -2.26 | -1.84 | -0.95 | -1.04 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today